AVROBIO (Nasdaq:AVRO) - Cotización, noticias y análisis

Resumen de acción AVRO

AVROBIO, Inc. es una empresa de terapia génica en fase clínica que desarrolla terapias génicas con células madre hematopoyéticas para tratar enfermedades raras en Estados Unidos.

Acerca de la empresa

AVRO fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

El ratio precio-beneficios (4.4x) es inferior al del mercado US (16.5x)

Se prevé un crecimiento anual de los beneficios de 8.36%

Ha pasado a ser rentable este año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

No tiene una capitalización de mercado significativa ($54M)

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de AVROBIO, Inc.

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$61.9m

Protalix BioTherapeutics

NYSEAM:PLX

US$87.7m

Spero Therapeutics

NasdaqGS:SPRO

US$77.3m

Serina Therapeutics

NYSEAM:SER

US$84.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for AVROBIO
Historical stock prices
Current Share Price	US$1.21
52 Week High	US$1.70
52 Week Low	US$0.57
Beta	1.24
1 Month Change	-0.82%
3 Month Change	-8.33%
1 Year Change	35.96%
3 Year Change	-89.49%
5 Year Change	-93.42%
Change since IPO	-96.12%

Noticias y actualizaciones recientes

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Rentabilidad de los accionistas

	AVRO	US Biotechs	Mercado US
7D	-0.8%	1.5%	1.2%
1Y	36.0%	1.1%	24.7%

Rentabilidad vs. Industria: AVRO superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.

Rentabilidad vs. Mercado: AVRO superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	6.5%
Biotechs Industry Average Movement	11.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: AVRO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AVRO ha disminuido de 15% a 6% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. es una empresa de terapia génica en fase clínica que desarrolla terapias génicas con células madre hematopoyéticas para tratar enfermedades raras en Estados Unidos. Sus terapias génicas emplean células madre hematopoyéticas extraídas del paciente y modificadas con un vector lentiviral para insertar el equivalente de una copia funcional del gen mutado en la enfermedad diana. La cartera de productos de la empresa incluye AVR-RD-02, que se encuentra en ensayos clínicos de fase 1/2 para el tratamiento de la enfermedad de Gaucher tipo 1 y 3; AVR-RD-01, que se encuentra en ensayos clínicos de fase 2 para el tratamiento de la enfermedad de Fabry; y AVR-RD-03 que está en fase preclínica para el tratamiento de la enfermedad de Pompe.

Resumen de fundamentos de AVROBIO, Inc.

¿Cómo se comparan los beneficios e ingresos de AVROBIO con su capitalización de mercado?
Estadísticas fundamentales de AVRO
Capitalización bursátil	US$54.28m
Beneficios(TTM)	US$12.16m
Ingresos (TTM)	n/a

4.5x

Ratio precio-beneficio (PE)

0.0x

Ratio precio-ventas (PS)

¿Está AVRO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AVRO
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	-US$12.16m
Beneficios	US$12.16m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.27
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado AVRO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción AVRO

Recompensas

Análisis de riesgos

Competidores de AVROBIO, Inc.

NasdaqGM:EGRX

US$61.9m

NYSEAM:PLX

US$87.7m

NasdaqGS:SPRO

US$77.3m

NYSEAM:SER

US$84.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease